Biofrontera Inc. (BFRI) Stock Price & How to Invest

Biofrontera Inc. is a US-based commercial-stage biopharmaceutical company that markets dermatology products, with its business centered on Ameluz, a topical photodynamic therapy (PDT) gel, used together with its RhodoLED family of red-light lamps. The primary approved use is treating actinic keratosis, common precancerous skin lesions caused by sun damage. The company sells to dermatology practices in the United States and reports high gross margins on the branded therapy, though it operates at a very small revenue base compared with large pharmaceutical peers.

By mid-2026, Biofrontera had been posting revenue growth: it reported roughly $41.7 million in full-year 2025 sales and continued double-digit year-over-year growth into the first quarter of 2026, with gross margins reported near 80%. Much of the investment narrative rests on pipeline and label-expansion catalysts. The FDA accepted a supplemental application for Ameluz PDT to treat superficial basal cell carcinoma, with a target decision date in late September 2026, and the company reported positive late-stage data for treating actinic keratosis on additional body areas and encouraging mid-stage data in acne.

Despite the momentum, BFRI remains a highly speculative micro-cap. It is heavily concentrated in a single product family, has historically needed capital and operated near or below profitability, and its shares have traded at very low, penny-stock-like levels, which raises considerations around volatility, dilution, and listing requirements. Investors typically treat it as an early, catalyst-driven story rather than an established, self-funding pharmaceutical business.

Biofrontera carries risks that are typical of a speculative micro-cap and then some. Revenue is concentrated in a single product family, so any competitive, reimbursement, or safety setback for Ameluz would hit the whole business. FDA outcomes on label expansions such as basal cell carcinoma are binary and could disappoint, and even approvals require commercial execution to matter. The company has historically operated near or below profitability and may need additional capital, raising the possibility of dilution for existing shareholders. Its shares have traded at very low, penny-stock levels, which can bring high volatility, liquidity constraints, and potential exchange-listing pressure. Larger dermatology and PDT competitors have deeper resources. Anyone considering BFRI should treat it as high-risk and verify the current financial and regulatory situation before acting.

A simple financial snapshot. These are approximations and refresh quarterly; for current figures see Biofrontera Inc.'s investor relations page or your broker.

• Revenue (TTM): Small but growing; full-year 2025 was roughly $40M with reported double-digit year-over-year growth continuing into 2026. Tiny versus large pharma peers.
• Profitability: Reported gross margins are high (near 80%), but the company has historically operated near or below net profitability at the bottom line.
• Balance sheet: Micro-cap with limited scale; may require additional financing over time, which can dilute existing holders. Verify current cash position live.
• Valuation: Trades as a speculative small-cap; conventional earnings-based multiples are of limited use when profitability is inconsistent. Sentiment is catalyst-driven.
• Catalysts: Key FDA decision on superficial basal cell carcinoma expected in late September 2026, plus pipeline updates in acne and additional treatment areas.
• Analyst view: Coverage is thin given the small size; views are highly dependent on regulatory outcomes and commercial ramp rather than steady fundamentals.

These figures are approximate and qualitative, drawn from recent public reporting, and are not precise or real-time. Biofrontera is a very small, volatile company whose numbers can change quickly. Always verify current revenue, cash, share count, and regulatory status from primary sources before making any decision.

There are three common ways to get BFRI exposure. Buy shares (or fractional shares) directly at any major broker. Hold an ETF that includes it, which spreads the position across many companies. Or build it into a focused thematic basket, so BFRI sits alongside other stocks that express the same thesis.

Walnut takes the basket route. Describe a thesis where BFRI fits (for example “AI infrastructure” or “dividend-growth large-caps”) and the AI proposes 5 to 6 constituents with target weights. You review the plan and fund it through your own broker when you're ready.

Biofrontera is a speculative dermatology micro-cap built around Ameluz photodynamic therapy. The bet is that growing branded PDT sales plus label expansions (basal cell carcinoma, acne) can scale a high-gross-margin franchise into sustained profitability. The risk is single-product concentration, cash needs, and regulatory dependence at penny-stock scale.